The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod. As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care. Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in aINCAT score over time
Timeframe: Up to 2 years and 3 months
Change in I-RODS score over time
Timeframe: Up to 2 years and 3 months
Change in grip strength over time
Timeframe: Up to 2 years and 3 months
Change in EQ-5D value from index date over time
Timeframe: Up to 2 years and 3 months